← Back to Search

Antisense Oligonucleotide

STP705 for Squamous Cell Carcinoma

Phase 2

Waitlist Available

Led By Edward Primka, MD

Research Sponsored by Sirnaomics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks

Awards & highlights

Study Summary

This trial is testing a new drug to treat skin cancer. The goal is to see if it is safe and effective.

Eligible Conditions

Squamous Cell Carcinoma in Situ

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of participants with histological clearance of treated isSCC lesion

Secondary outcome measures

Change in size of the treated isSCC lesion

Trial Design

7Treatment groups

Experimental Treatment

Group I: Part 2: Arm DExperimental Treatment1 Intervention

Placebo (normal saline), intralesional injection, given once a week for 6 weeks.

Group II: Part 2: Arm A, B or CExperimental Treatment1 Intervention

STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.

Group III: Part 2: Arm A or B or CExperimental Treatment1 Intervention

STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.

Group IV: Part 1: Arm DExperimental Treatment1 Intervention

Placebo (normal saline), intralesional injection, given once a week for 6 weeks.

Group V: Part 1: Arm CExperimental Treatment1 Intervention

STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.

Group VI: Part 1: Arm BExperimental Treatment1 Intervention

STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.

Group VII: Part 1: Arm AExperimental Treatment1 Intervention

STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

STP705

2022

Completed Phase 2

~180

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

SirnaomicsLead Sponsor

11 Previous Clinical Trials

293 Total Patients Enrolled

Edward Primka, MDPrincipal InvestigatorDermatology Associates of Knoxville

Girish Munavalli, MDPrincipal InvestigatorDermatology, Laser and Vein Specialists of the Carolinas

5 Previous Clinical Trials

821 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the prevalence of this research effort in the United States?

"Six clinical trial sites are now running this study, with locations in Aventura, West Palm Beach and Nashville amongst others. It is beneficial to select the nearest site possible to decrease the amount of travel needed if you become a participant."

Answered by AI

What potential risks do patients face when taking STP705?

"Our expert team at Power assigned STP705 a safety rating of 2, as existing evidence indicates its safe use but no data is available to support the efficacy of this medication."

Answered by AI

Are there any limits to the size of this experiment's participant pool?

"For the trial to commence, Sirnaomics is in need of a hundred patients that satisfy their eligibility requirements. The research will be taking place at Center for Clinical and Cosmetic Research in Aventura, Florida and Research Institute of the Southeast LLC in West Palm Beach, Arizona."

Answered by AI

Is there still capacity for participants in this investigation?

"Affirmative. Information on clinicaltrials.gov suggests that this medical trial is actively recruiting and has been since May 18th 2021, with the latest update being made October 24th 2022. The researchers are in need of 100 participants distributed across 6 locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

2021. "A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04844983.